by Brad Dunn | Jan 18, 2021
Stephanie Brown, the SVP of rare diseases at Ipsen Biopharmaceuticals, describes the company’s involvement with the International Fibrodysplasia Ossificans Progressiva Association (IFOPA). “It’s so inspiring to recently attend the Family Gathering, which is an...
by Brad Dunn | Jan 17, 2021
Ally Roets and her son Sam — who was diagnosed with facioscapulohumeral muscular dystrophy (FSHD) when he was age 6 — describe the various therapies they have pursued to mitigate the impact of the disease. FSHD is a rare disabling disease characterized by...
by Brad Dunn | Jan 17, 2021
Dr. Anna Sureda, Head of the Onco-Hematology Service at Blood Cell Barcelona, gives an overview of the ECHELON-1 study of brentuximab vedotin as a frontline treatment for late-stage Hodgkin lymphoma. The trial finished in 2017. The primary objective of the...
by Brad Dunn | Jan 16, 2021
Elizabeth Thompson, PhD at Horizon Therapeutics discusses the challenges of diagnosing thyroid eye disease (TED), a rare autoimmune disease causing permanent facial disfigurement severely affecting patients’ quality of life and daily function. The disease often...
by Brad Dunn | Jan 15, 2021
Stephanie Brown, the SVP of rare diseases at Ipsen Biopharmaceuticals, describes the company’s commitment to working closely with patients to better understand their conditions. “Rare disease is a unique space, and we really get to know patients directly,”...